C4 Therapeutics, Inc.(CCCC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,812 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CCCC
Events flagged as statistical outliers against CCCC's own multi-year baseline — not fixed dollar thresholds.
CCCC Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for C4 Therapeutics, Inc. (CCCC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCCC at 18.2/100 on a 32-signal composite quality model, placing it at rank #2,812 of 2,962 stocks — the bottom half of the AI-ranked universe. CCCC scores in the top quartile across institutional flow (97.6). Areas of concern include free cash flow (4.0) and profitability (4.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), C4 Therapeutics, Inc. reports quarterly revenue of $6.6M, net income of $-23.6M, free cash flow of $-1.6M. Top institutional holders of CCCC by reported 13-F value include MORGAN STANLEY, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. CCCC trades on the Nasdaq exchange and files with the SEC under CIK 1662579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for C4 Therapeutics, Inc. directly from SEC EDGAR. C4 Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 23 since 2023, currently 18.2 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$6.6M
Net Income
Q2 2026
$-23.6M
Free Cash Flow
Q2 2026
$-1.6M
ROIC
Q2 2026
-42.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1.0% YoYNet Income
+0.3% YoYOperating Income
+3.7% YoYEPS (Diluted)
+16.4% YoYTotal Assets
+2.7% YoYTotal Debt
Op. Cash Flow
-51.5% YoYFree Cash Flow
-52.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $35.9M +1.0% | $35.6M +71.4% | $20.8M -33.3% | $31.1M -32.1% | $45.8M | — |
| Net Income | $-105.0M +0.3% | $-105.3M +20.5% | $-132.5M -3.4% | $-128.2M -52.8% | $-83.9M -26.5% | $-66.3M |
| Operating Income | $-115.2M +3.7% | $-119.6M +14.0% | $-139.0M -7.3% | $-129.5M -57.7% | $-82.1M -35.9% | $-60.4M |
| EPS (Diluted) | $-1.27 +16.4% | $-1.52 +43.1% | $-2.67 -1.9% | $-2.62 -44.0% | $-1.82 | — |
| Total Assets | $359.1M +2.7% | $349.6M -7.1% | $376.5M -12.6% | $430.8M -15.0% | $506.8M +26.6% | $400.1M |
| Total Debt | — | — | $0.00 -100.0% | $13.8M +27.9% | $10.8M +7.1% | $10.1M |
| Operating Cash Flow | $-98.7M -51.5% | $-65.2M +39.0% | $-106.8M -0.8% | $-105.9M -21.8% | $-87.0M -29.3% | $-67.2M |
| Free Cash Flow | $-99.3M -52.0% | $-65.3M +39.8% | $-108.5M +2.6% | $-111.4M -26.3% | $-88.2M -30.0% | $-67.9M |
Get alerted when CCCC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for C4 Therapeutics, Inc. including:
Top Institutional Holders of CCCC
MORGAN STANLEY
$41.4M8,867,338 shRA CAPITAL MANAGEMENT, L.P.
$37.4M8,000,000 shBlackRock, Inc.
$36.9M7,896,718 shLynx1 Capital Management LP
$34.2M7,326,691 shSquadron Capital Management LLC
$33.6M7,200,000 shBain Capital Life Sciences Investors, LLC
$33.5M7,171,910 shJPMORGAN CHASE & CO
$20.7M4,747,424 shVANGUARD CAPITAL MANAGEMENT LLC
$20.6M4,417,731 shCITADEL ADVISORS LLC
$19.6M4,187,580 shGOLDMAN SACHS GROUP INC
$16.5M3,530,991 sh
| Fund | Value | Shares |
|---|---|---|
| MORGAN STANLEY | $41.4M | 8,867,338 |
| RA CAPITAL MANAGEMENT, L.P. | $37.4M | 8,000,000 |
| BlackRock, Inc. | $36.9M | 7,896,718 |
| Lynx1 Capital Management LP | $34.2M | 7,326,691 |
| Squadron Capital Management LLC | $33.6M | 7,200,000 |
| Bain Capital Life Sciences Investors, LLC | $33.5M | 7,171,910 |
| JPMORGAN CHASE & CO | $20.7M | 4,747,424 |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.6M | 4,417,731 |
| CITADEL ADVISORS LLC | $19.6M | 4,187,580 |
| GOLDMAN SACHS GROUP INC | $16.5M | 3,530,991 |
Companies Similar to CCCC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Prelude Therapeutics Inc
Relay Therapeutics, Inc.
MACROGENICS INC
Xencor Inc
Intellia Therapeutics, Inc.
BioAge Labs, Inc.
SUTRO BIOPHARMA, INC.
Roivant Sciences Ltd.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CCCC on your watchlist
Track score changes the day C4 Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CCCC a good stock to buy?
13F Pro's AI-powered analysis of C4 Therapeutics, Inc. (CCCC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CCCC are available on the CCCC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CCCC is classified as a small company.
Which hedge funds own CCCC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CCCC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of C4 Therapeutics, Inc.'s investment landscape.